Multiple studies demonstrate that co-administration of NMDA receptor antagonists with morphine attenuates the development of analgesic tolerance. Sex differences in the effects of non-competitive, but not competitive NMDA receptor antagonists on acute morphine analgesia have been reported in mice, yet the role of sex in modulation of morphine tolerance by NMDA receptor antagonists has yet to be addressed. Therefore, we tested whether there is a sex difference in the effect of NMDA receptor antagonists on the development of morphine analgesic tolerance in C57BL/6J mice. Acutely, at a dose required to affect morphine tolerance in male mice, the non-competitive NMDA receptor antagonist MK-801 prolonged morphine analgesia similarly in both sexes in the hot plate and tail withdrawal assays. In the hot plate assay, co-administration of MK-801 or the competitive antagonist CPP [3-(2-carboxpiperazin-4-yl)propyl-1-phospionic acid] with morphine attenuated the development of tolerance in male mice, while having no effect in females. Like normal and sham females, ovariectomized mice were similarly insensitive to the attenuation of morphine tolerance by MK-801 in the hot plate assay. Surprisingly, in the tail withdrawal assay, MK-801 facilitated the development of morphine-induced hyperalgesia and tolerance in males but not females. The results demonstrate that male mice are more sensitive to modulation of nociception and morphine analgesia following repeated co-administration of NMDA receptor antagonists with morphine but that the underlying mechanisms are likely to be different from those mediating the sex difference in the modulation of acute morphine analgesia that has previously been reported.
INTRODUCTION
Analgesic tolerance to opioid drugs is a clinical problem because progressively higher doses are required for chronic pain relief, which can limit the safety and exacerbate withdrawal symptoms. In addition to opioid receptor-level cellular adaptations associated with tolerance (reviewed by (5) , a separate focus of tolerance mechanisms highlights the importance of systems adaptations that oppose the acute effects of opioids (e.g., glutamate, substance P, cholecystokinin, and dynorphin) and contribute to opponent behavioral and psychological responses associated with tolerance and dependence (e.g., hyperalgesia and dysphoria; recently reviewed by (11)). Adaptations such as hyperalgesia can have an associative learning component which contribute to tolerance (58) .
Many studies have shown that co-administration of non-competitive or competitive NMDA receptor antagonists can attenuate the development of analgesic tolerance to morphine in rodents (62) but the mechanism of this effect remains unclear. It is believed that NMDA receptor antagonists block calcium-mediated signaling and the resulting changes in gene expression and neuroplasticity that mediate morphine tolerance.
In considering the mechanisms by which NMDA receptor antagonists disrupt morphine tolerance, it may be useful to consider their effects on acute morphine analgesia. Although some studies indicate that NMDA receptor antagonists potentiate or prolong morphine analgesia, others show no difference or just the opposite. Discrepancies may be ultimately explained by many different factors including the type and dose of antagonist (16) , morphine dose, sex (51), species, strain, route of drug administration, injection-to-test interval, antagonist-to-morphine interval, and type of nociceptive assay, to name a few.
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It was recently reported that non-competitive NMDA receptor antagonists (MK-801 and dextromethorphan) enhanced acute morphine analgesia in male but not female mice (25, 51) .
The lack of enhancement by dextromethorphan in females was estrogen-dependent as ovariectomized (ovx) mice showed a male-like enhancement and estrogen replacement reinstated the female phenotype (25) . In contrast, the competitive NMDA receptor antagonist LY235959 enhanced morphine analgesia equally in both sexes (51) . In rats, sex differences in the modulation morphine analgesia by MK-801 have also been reported with one report indicating that males were more sensitive (16) and another report demonstrating that females were more sensitive (29) . The discrepancy may be due to an interaction of different doses of MK-801 and morphine.
It is unclear whether the effects of NMDA receptor antagonists on acute morphine analgesia are related to their ability to affect morphine tolerance. Simonnet and colleagues have proposed that the enhancement of acute morphine analgesia by NMDA receptor antagonists is due to a blockade of an opponent hyperalgesia (c.f., "acute" tolerance) that is unmasked by an opioid receptor antagonist following the first opioid exposure (13, 40, 59) . From this view, opioid tolerance has been conceptualized as a pain "sensitization" process whereby repeated intermittent administration of opioids results in a progressive increase in the activation of pain facilitatory systems (13, 14) . Thus, if repeated hyperalgesia induces the changes in gene expression and neuroplasticity that mediates this sensitization process associated with tolerance and if the male-specific enhancement of acute morphine analgesia in mice is actually a malespecific blockade of acute hyperalgesia, then chronic co-administration of the non-competitive NMDA receptor antagonist MK-801 with morphine should attenuate the development of morphine tolerance in male, but not female mice. In contrast, because qualtitatively similar Page 4 of 42 effects were observed previously with competitive NMDA receptor antagonists on acute morphine analgesia, the prediction is that co-administration of the competitive NMDA receptor antagonist CPP with morphine would attenuate the development of morphine tolerance in both male and female mice.
In pilot experiments, we first determined doses of MK-801 and CPP that were required to attenuate morphine tolerance in male mice. We then used these doses to examine the modulation of morphine tolerance in male and female mice. Upon observing a sex difference in the modulation of tolerance in the hot plate and tail withdrawal assays, we then determined at the doses required to affect morphine tolerance, if there was a sex difference in the modulation of acute morphine analgesia by MK-801. For clarity, in each experiment, the acute data is presented first followed by the tolerance data.
MATERIALS AND METHODS

Animals and surgery
Male and female C57BL/6J mice were obtained from either Jackson Laboratories (hot plate; Jackson Laboratories, Bar Harbor, ME; JAX) or from a breeding facility on the UCLA campus (tail withdrawal) and were 8-12 weeks old at the start of the experiments. Ovariectomies were performed at 8 weeks of age in JAX mice as previously described (48). Briefly, mice were anesthetized with ketamine/zylazine (100 mg/kg, 10 mg/kg, i.p., respectively) and the skin and abdominal wall overlying the ovary were incised. The ovary and uterine horn were exposed.
The uterine horn was clamped with a hemostat proximal to the ovary and ligated with dissolvable suture. The ovary was cut from the uterine horn and removed and the uterine horn replaced in the body cavity. The abdominal wall was sutured with sterile 5-0 gut and the overlying skin was closed with wound clips. Sham mice were anethetized and the skin and abdominal wall overlying the ovary were incised. The abdominal wall was sutured with sterile 5-0 gut and the overlying skin was closed with wound clips. Mice were allowed at least one month to recover before testing. Although no biochemical assay was conducted to measure estrogen levels, ovx mice weighed significantly more than shams (t(83)=-4.82; p<0.0001) and their hair grew back much faster than sham mice following surgery. Both of these observations are consistent with elimination of estrogen function (3, 15, 24, 57) . All mice were housed in a climate-controlled vivarium, had unlimited access to food and water, and were on a 12:12 light dark cycle. Treatment and testing were always conducted during the light part of the cycle.
Experiments were conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committee. Separate animals were always used or each pain assay, for each acute experiment, for each tolerance experiment, and for each treatment.
Drugs
Morphine sulfate was obtained from NIDA (Bethesda, MD). The non-competitive NMDA receptor antagonist MK-801 (dizocilipine) and the competitive NMDA receptor antagonist CPP [3-(2-carboxpiperazin-4-yl)propyl-1-phospionic acid] were purchased from Sigma (St. Louis, MI). Limited reports investigating the competitive NMDA receptor antagonist D-CPPene (the active analog of ±CPP) suggest that similar, to other competitive antagonists, this drug potentiates (7), or at least, prolongs morphine analgesia (9) in males. All drugs were dissolved in physiological saline (0.9% NaCl) and administered in a volume of 10 ml/kg.
Pain assays
We used two different pain assays to measure morphine analgesia. First, we used the 52.5°C hot plate assay (20) where the mice were placed on a hot metal surface and the latency to lick the hindpaw was recorded to the nearest 0.1s using a stopwatch. A cut-off of 60 s was employed to prevent tissue damage.
In order to test the generality of the hot plate findings to another pain assay, we also used the 49.0°C tail withdrawal/immersion assay (8) . Here, the mice were momentarily placed in a restraint made of cotton and the distal half of their tails were immediately placed into a circulating water bath that was accurate to the nearest 0.1°C. The latency to flick the tail was recorded with a stopwatch to the nearest 0.1s. A cut-off of 15 s was employed to prevent tissue damage. The experimenter was always blind on test day to pre-treatment conditions.
Acute morphine analgesia
In order to test for MK-801 modulation of acute morphine analgesia and tolerance, different doses of MK-801 were used in the hot plate and tail withdrawal assays. This is because the drug regimen using a constant dose of morphine and MK-801 (10 mg/kg and 0.25 mg/kg, respectively) did not produce tolerance in the tail withdrawal assay. Using a second regimen of escalating doses of morphine to induce tolerance in both assays, we found that a higher dose of MK-801 (1 mg/kg) was required to affect tolerance and thus, this dose was examined in the tail withdrawal assay.
In examining acute morphine analgesia in the hot plate assay, mice were measured for baseline latencies once per day for three days prior to analgesic assessment. This was done in order to eliminate any learning effect on the hot plate latencies in order to maximize the possibility for detecting a true MK-801-induced hyperalgesia (1) . No significant differences were observed between days 2 and 3 so these values were averaged and presented as the baseline latency ("0 min post-injection"; Figure 1 A, B) . Thirty min following the last baseline measurement, mice were administered MK-801 (0.25 mg/kg, i.p.) followed 30 min later by morphine (7.5 mg/kg, s.c.; "MK+mor"). Mice receiving morphine alone were administered an i.p. injection of saline followed 30 min later by morphine (7.5 mg/kg, s.c.; "mor"). "Control" mice were given two saline injections (i.p. and s.c.), separated by 30 min. Mice receiving MK-801 alone ("MK") were administered MK-801 (0.25 mg/kg, i.p.) followed 30 min later by a saline injection (s.c.). Post-injection latencies were determined every 30 min for 90 min.
In examining the effect of MK-801 on acute morphine analgesia in the tail withdrawal assay, two separate baseline measurements were recorded, separated by 30 min. No significant differences were observed, thus, they were averaged and presented as the baseline ("0 min postinjection"; Figure 4 A, B). Thirty min later, mice were administered MK-801 (1 mg/kg, i.p.) followed immediately by morphine (7.5 mg/kg, s.c.; "MK+mor"). Mice receiving morphine alone were administered an i.p. injection of saline followed immediately by morphine (7.5 mg/kg, s.c.; "mor"). "Control" mice were administered two saline injections (i.p. and s.c.). Mice receiving MK-801 alone ("MK") were administered MK-801 (1 mg/kg, i.p.) followed immediately by a saline injection (s.c.). Post-injection latencies were measured from 30 to 90 min. Examination of the interaction of MK-801 with higher doses of morphine (20-40 mg/kg) was not possible because all mice reached cut-off latency.
Morphine analgesic tolerance in the hot plate assay using a constant dose of morphine
In the hot plate assay, naïve mice were treated twice daily for 6 days with MK-801 (0.25 mg/kg, i.p.) followed 30 min later by morphine (10 mg/kg, s.c.; "MK+mor") (26). The other groups were treated as described for the acute experiment. Injections were conducted at 900 h and 1800 h. On day 7 at 900 h, mice were tested for baseline hot plate latencies and 30 min later, given a challenge dose of morphine (10 mg/kg, s.c.). Post-injection latencies were measured from 30-90 min. Tolerance was indicated by a change in morphine analgesic efficacy following a challenge dose as previously employed (26).
Morphine analgesic tolerance in the hot plate and tail withdrawal assays using escalating doses of morphine A second tolerance regimen adapted from a previously published protocol (21) was also examined. This was done in order to eliminate the possibility that the hot plate results were due to specific parameters of drug administration and because tolerance did not develop in the tail withdrawal assay under the regimen of a constant dose of morphine. Mice were administered escalating doses of morphine (10-40 mg/kg, subcutaneously, (s.c.) once per day for 6 days. MK-801 (1 mg/kg, i.p.) was co-administered immediately following morphine and then 2 h later (1 mg/kg, i.p.; "MK+mor"). CPP was co-administered simultaneously with morphine (30 mg/kg, intraperitoneally; i.p.) and then 2h later (30 mg/kg, i.p.; "CPP+mor"). The other groups were treated as described for the acute experiment except for the extra injection of saline (i.p.;
"control", "mor") or antagonist (i.p.; "MK", "CPP") 2h later. The doses of antagonists for this second tolerance regimen were chosen based on pilot hot plate data using males where we found that lower doses of antagonists with morphine were completely ineffective in attenuating the development of morphine tolerance. Additionally, we found that a second injection of antagonist was necessary to attenuate morphine tolerance and we chose 2 h based on a previous study indicating that the half-life of MK-801 is approximately 2 h (64). Injections were conducted at 1000 h and 1200 h. On day 7 at 1000 h, baseline latencies were first recorded with the hot plate or tail withdrawal assay. Thirty min later, all mice received either 10 mg/kg s.c. morphine (hot plate) or 7.5 mg/kg s.c. morphine (tail withdrawal). Post-injection latencies were recorded every 30 min from 30-90 min and are presented as the percent maximum possible effect as defined in the analysis. As with the regimen of a constant dose of morphine, morphine tolerance was indicated by a change in analgesic efficacy following a single challenge dose. Because this regimen of escalating doses produced a more prolonged tolerance and attenuation of tolerance by MK-801 in males in the hot plate assay, this regimen was employed in the ovariectomy experiment ( Figure 3 ).
Analysis
In the acute experiments, two-way repeated measures ANOVA of post-injection latencies from 30 to 90 min followed by planned comparison was used for analysis. Paired t-test was used in the case of MK-801-induced hyperalgesia that was observed in the tail withdrawal assay. In the tolerance experiments, due to the changes in baseline latencies following repeated administration, post-injection latency values were converted to percent maximum possible effect (%MPE) for each individual animal with respect to each individual baseline value according to the following formula: %MPE = (post-injection latency -baseline latency) / (60 -baseline latency) * 100. Because there was no interaction over time, %MPE values were averaged from 30 to 90 min and two-way ANOVA followed by planned comparison was employed. The only exception was with Figure C and D, in which there was a three-way interaction of time, sex and treatment. In this instance, two-way repeated measures ANOVA followed by planned comparison was used for analysis. For the tail withdrawal, because tolerance was only significant at 30 min, this was the time point used in analysis of the %MPE data. For all experiments involving repeated drug administration, area under the curve (AUC; min x %MPE) was estimated from 0-90 min using the trapezoid method. In all analyses, an alpha level of 0.05 was considered significant.
RESULTS
In the hot plate assay, MK-801 prolongs acute morphine analgesia in male and female mice
We observed a similar prolongation of acute morphine analgesia by MK-801 in both sexes in the hot plate assay ( Figure 1A , B). There was a main effect of treatment (F3,47=74.7; p<0.0001), time (F2,94=7.4; p=0.001), and an interaction of treatment with time (F6,94=8.0; p<0.001). In comparing mice receiving morphine alone ("mor") with mice receiving MK-801 plus morphine ("MK+mor"), co-administration prolonged morphine analgesia at 90 min in both males (F6,94=5.0; p<0.05) and females (F6,94=4.9; p<0.05). There was no change in baseline latency following saline ("control") or MK-801 alone ("MK") over 90 min in either sex, nor did MK-801 itself have any effect on initial baseline latencies within each animal ( Figure 1A , B).
In the hot plate assay, following a constant dose of morphine, MK-801 attenuates the development of morphine tolerance in male, but not female mice
In separate naïve mice, following the regimen of repeated administration of constant doses of morphine and MK-801, we found that co-treatment produced a subsequent malespecific increase in baseline latency (herein referred to as baseline "hypoalgesia") ( Table 1) which was accompanied by a male-specific attenuation of the development of morphine tolerance (Figure 1 C) .
In Table 1 , in examining changes in baseline latencies following repeated administration, Fisher's PLSD indicated that male, but not female mice receiving repeated MK-801 plus morphine ("MK+mor") demonstrated significant baseline hypoalgesia relative to "control" mice (p<0.05).
In Figure 1C , D, in examining modulation of morphine tolerance following repeated administration and a subsequent morphine challenge, there was a main effect of treatment (F3,80=20.7; p<0.0001) and a treatment by sex by time interaction (F6,160=2.3; p<0.05). In comparing "mor" versus "control" groups, significant tolerance developed at 30, 60, and 90 min males (F6,160=5.6; p<0.05; F3,80=9.2; p<0.01; F3,80=8.4; p<0.01) whereas in females, tolerance was significant only at 30 and 60 min (F6,160=6.9; p<0.05, F3,80=10.2; p<0.01). In males, in comparing "mor" and "MK+mor" groups, the development of morphine tolerance was attenuated with MK-801 only at 30 min (F6,160=3.9; p=0.05). In females, there was no effect of MK-801 on the development of morphine tolerance ( Figure 1C , D).
In Figure 1E , F, in examining AUC, there was a main effect of treatment (F3,80=21.7; p<0.0001). In comparing "mor" and "control" mice, significant tolerance developed in both male (F3,80=17.0; p<0.0001) and female mice (F3,80=13.2; p<0.001). In comparing "MK+mor" with "control" mice, tolerance also developed in males (F3,80=8.1; p<0.01) and females (F3,80=10.6; p<0.01). In comparing "mor" mice with "MK+mor" mice, co-administration of MK-801 with morphine had no effect on the development of tolerance in male or female mice ( Figure 1E, F) .
In the hot plate assay, following escalating doses of morphine, MK-801 and CPP attenuate the development of morphine analgesic tolerance in male, but not female mice Using separate naïve mice, repeated co-administration of MK-801 or CPP with escalating doses attenuated the development of morphine analgesic tolerance in male, but not female mice ( Figure 2 ). With respect to MK-801, this was accompanied by a male-specific baseline hypoalgesia following co-administration (Table 2) .
In Table 2 , in examining differences in baseline latencies following repeated administration in the MK-801 experiment, there was a main effect of treatment (F3,91=7.3; p<0.001) and sex (F1,91=7.3; p<0.01). Male mice receiving MK-801 plus morphine ("MK+mor") and those receiving just MK-801 alone ("MK") exhibited significantly higher baseline latencies than "control" mice on test day (F3,91=7.2; p<0.01; F3,91=14.7; p<0.001, respectively). In contrast, only female mice receiving repeated MK-801 alone ("MK") exhibited baseline hypoalagesia relative to "control" mice receiving repeated saline (F3,91=5.9; p<0.05).
In examining possible changes in baseline latencies after repeated co-administration of CPP with morphine, there was no effect on either sex (Table 2) .
In Figure 2A , B, in examining the modulation of morphine tolerance by MK-801, there was a main effect of treatment (F3,91=31.8; p<0.0001) and an interaction of treatment and sex (F1,91=2.90; p<0.05). In comparing "control" and "mor" mice, significant tolerance developed in both males (F3,91=48.8; p<0.0001) and females (F3,91=19.04; p<0.0001). However, in comparing "mor" mice with "MK+mor" mice, co-administration of MK-801 attenuated the development of tolerance in males (F3,91=11.5; p<0.01), but not females (Figure 2A, B) .
In Figure 2C , D in examining AUC, there was a main effect of treatment (F3,91=36.2; p<0.0001) and an interaction of treatment with sex (F3,91=3.2; p<0.05). In comparing "mor" mice with "control" mice, significant tolerance developed in both males (F3,91=53.4; p<0.0001) and females (F3,91=23.2; p<0.0001). In comparing "mor" with "MK+mor" mice, coadministration of MK-801 with morphine attenuated the development of tolerance in males (F3,91=12.3; p<0.001), but not females. The attenuation in males was incomplete as "MK+mor" mice still exhibited significant tolerance relative to "control" (F3,91=14.4; p<0.001). Female mice receiving MK-801 and morphine ("MK+mor") exhibited tolerance relative to "control" mice (F3,91=28.5; p<0.0001) that was similar to mice receiving morphine alone ("mor") ( Figure   2C , D).
In male mice, a lower dose of MK-801 (0.3 mg/kg, i.p.) was completely ineffective in attenuating the development of morphine tolerance under the regimen of escalating doses of morphine (data not shown). Specifically, in examining AUC, there was a main effect of treatment (F3,24=15.7; p<0.0001). Compared to mice receiving repeated saline ("control"), Fisher's PLSD indicated that significant tolerance developed in mice receiving repeated morphine ("mor"; p<0.001) and in mice receiving repeated MK-801 plus morphine ("MK+mor"; p<0.001) and that "mor" mice and "MK+mor" mice did not differ from each other (p>0.05).
In Figure 2E , F, in the CPP experiment, following repeated administration and a subsequent morphine challenge, there was a main effect of treatment (F2,61=21.2; p<0.0001), sex (F1,61=19.7; p<0.0001), and an interaction of treatment with sex (F2,61=7.2; p<0.01). In comparing "control" and "mor" mice, tolerance developed in both males (F2,61=17.5; p<0.0001) and females (F2,61=20.5; p<0.0001). In males, the development of tolerance was attenuated by co-administration of CPP with morphine as "CPP+mor" mice differed significantly from "mor" mice (F2,61=9.0; p<0.01). In contrast, in females, there was no effect of co-administration on tolerance as "CPP+mor" mice differed from "control" mice (F2,61=28.5; p<0.0001), but not "mor" mice ( Figure 2E , F).
In Figure 2G , H in examining AUC, there was a main effect of treatment (F2,61=20.7; p<0.0001), sex (F1,61=18.9; p<0.0001), and an interaction of treatment with sex (F2,61=7.5; p<0.01). In comparing "mor" mice with "control" mice, significant tolerance developed in both males (F2,61=16.1; p<0.001) and females (F2,61=20.8; p<0.0001). In comparing "mor" with "CPP+mor" mice, co-administration of CPP with morphine completely blocked the development of morphine tolerance in males as these groups differed significantly from each other (F2,61=9.0; p<0.01) and "CPP+mor" mice did not differ from "control" mice. In females, coadministration had no effect on the development of morphine tolerance as "CPP+mor" mice differed from "control" mice (F2,61=28.5; p<0.0001), but not from "mor" mice ( Figure 2G, H) .
We did not run a group receiving repeated CPP alone. This does not in any way limit the interpretation of the data because importantly, there was no change in baseline latency after repeated CPP plus morphine ("CPP+mor") relative to "control" mice and in a separate experiment, we found no effect of repeated administration of CPP alone on baseline latencies in either males (t(12)<1) or females (t(12)<1) (data not shown).
Ovariectomy has no effect on the lack of attenuation of the development of morphine analgesic tolerance by MK-801
Because morphine tolerance and the male-specific attenuation of tolerance with MK-801 in the hot plate assay were both more prolonged following the second regimen employing escalating doses of morphine, we used this regimen for examining the effect of MK-801 on the development of morphine tolerance in sham and ovx mice. In order to minimize the number of mice used, the group receiving repeated MK-801 alone ("MK") was excluded because we previously demonstrated that there was no effect of repeated MK-801 on subsequent acute morphine analgesia in either sex (Figure 2A, B) . The results indicate that following repeated coadministration of MK-801 plus morphine, ovx instated the male-like baseline hypoalgesia (Table   2 ). However, like sham mice, ovx mice were insensitive to modulation of the development of morphine tolerance following repeated administration of MK-801 with morphine ( Figure 3 ).
In Table 2 , in examining possible changes in baseline latencies following repeated administration, there was a main effect of treatment (F2,79=5.0; p<0.01). Significant baseline hypoalgesia developed in ovx mice treated with MK-801 plus morphine (F2,79=9.3; p<0.01) ( Table 2 ).
In Figure 3A , B, following repeated administration and a subsequent morphine challenge, there was a main effect of treatment (F2,79=17.1; p<0.0001). In comparing "mor" with "control" mice, significant tolerance developed in sham mice (F2,79=12.5; p<0.001) and as expected, co-treatment with MK-801 ("MK+mor") had no effect on the development of tolerance. Significant morphine tolerance also developed in ovx mice (F2,79=13.2; p<0.001) and similar to sham, co-treatment with MK-801 had no effect on the development of tolerance ( Figure 3A, B) .
In Figure 3C , D, in examining AUC, there was a main effect of treatment (F2,79=18.2; p<0.0001). In comparing "mor" mice with "control" mice, significant tolerance developed in both sham (F2,79=13.7; p<0.001) and ovx mice (F2,79=14.4; p<0.001). In comparing "mor" mice with "MK+mor" mice, co-administration of MK-801 with morphine had no effect on the development of tolerance in either sham or ovx mice. Additionally, "MK+mor" mice differed significantly from "control" sham mice (F2,79=13.8; p<0.001) and "control" ovx mice (F2,79=12.8; p<0.001), indicating tolerance ( Figure 3C, D) .
In the tail withdrawal assay, MK-801 prolongs acute morphine analgesia in male and female mice As with the hot plate assay, in the tail withdrawal assay, MK-801 prolonged morphine analgesia in both sexes. In Figure 4A and 60 min (p<0.05) and in males, also at 90 min (p<0.05) ( Figure 4A, B) .
In the tail withdrawal assay, following escalating doses of morphine, MK-801 facilitates the development of morphine analgesic tolerance in male, but not female mice
In the tail withdrawal assay, MK-801 enhanced the development of morphine-induced hyperalgesia and facilitated the development of tolerance in males, but not females (Table 2; Figure 4 ). In Table 2 , in naïve mice, in examining changes in baseline latencies following repeated administration, there was a main effect of treatment (F3,80=12.8; p<0.0001) and sex (F1,80=16.5; p<0.001). In comparing "mor" mice with "control" mice, morphine-induced hyperalgesia developed in males and females (F3,80=6.0; p<0.05; F3,80=9.9; p<0.01, respectively) as previously reported with this same protocol in males (11) . However, in comparing "mor" mice with "MK+mor" mice, the development of morphine-induced hyperalgesia was potentiated by repeated co-administration of MK-801 in males (F3,80=4.6; p<0.05), but not females ( Table 2 ).
In Figure 4C , D, following repeated administration and a subsequent morphine challenge, at 30 min, there was a main effect of treatment (F3,80=8.6; p<0.0001) and sex (F1,80=9.1; p<0.01). In comparing "mor" mice with "control" mice, significant tolerance developed in both males (F3,80=4.8; p<0.05) and females (F3,80=8.4; p<0.01). Furthermore, cross-tolerance developed to morphine in male and female mice receiving repeated administration of MK-801 alone because there was a significant decrease in morphine analgesia in these mice relative to control mice ("MK" vs "control") (F3,80=4.9; p<0.05; F3,80=7.9; p<0.01) in the absence of any change in baseline latency (Figure 4C , D; Table 2 ).
In Figure 4E , F, examining AUC, there was a main effect of treatment (F3,80=5.3; p<0.01) but no effect of sex (F1,80=3.7; p=0.06). In examining tolerance in this manner, in comparing "mor" mice with "control" mice, tolerance did not develop in males but developed in females (F3,80=6.2; p<0.05). In male mice, the AUC of "MK+mor" mice was marginally less than "mor" mice (F3,80=2.7; p=0.1) and significantly less than "control" mice (F3,80=7.0; p<0.01), indicating that co-administration of MK-801 facilitated the development of morphine tolerance in males. Cross-tolerance of male mice receiving repeated MK-801 alone ("MK") was not significant compared to "control" mice when considering the entire time-effect curve. In females, co-administration had no effect on tolerance as "MK+mor" mice did not differ from "mor" mice, but differed from "control" mice (F3,80=7.0; p<0.01). Last, female mice that received repeated MK-801 alone ("MK") exhibited cross-tolerance to the analgesic effect of morphine as the AUC of this group was significantly less than that of the "control" group receiving repeated saline (F3,80=7.9; p<0.01) ( Figure 4E and F) . This occurred in the absence of any change in baseline latency ( Table 2) .
DISCUSSION
In the present study, the non-competitive NMDA receptor antagonist MK-801 prolonged acute morphine analgesia equally in males and females in both the hot plate and tail withdrawal assays, yet at the same doses, produced a male-specific attenuation of morphine tolerance in the hot plate assay and a male-specific facilitation of tolerance in the tail withdrawal assay. Because we examined the difference in efficacy of a single challenge dose of morphine (26), it was not possible to quantify the degree of tolerance nor the degree of modulation of tolerance. Thus, it is possible that if tolerance were assessed in a different manner (e.g., via cumulative dose-response curves or a different morphine dose), different results might be observed.
MK-801 was previously reported to enhance acute morphine analgesia only in male mice whereas competitive NMDA receptors enhanced morphine analgesia equally in both sexes (51) .
The lack of sex difference in the modulation of acute morphine analgesia in the present study is likely due to the higher dose of MK-801 that was examined (which was required to affect morphine tolerance) and/or the lower dose of morphine.
In the first report of sex differences in MK-801 modulation of morphine analgesia, there was a male-specific attenuation of morphine analgesia by MK-801 in deer mice (44) . The discrepancy of this result with the more recent finding (51) and our study is likely due to the extremely low dose of morphine utilized by Kavaliers and colleagues (1 mg/kg, (44)). Indeed, the non-competitive NMDA receptor antagonist dextromethorphan produced a male-specific decrease in morphine analgesia at lower morphine doses and a male-specific enhancement at higher doses, whereas MK-801 enhanced morphine analgesia in males at all doses (51).
Regardless, because our regimen produced a similar prolongation of acute morphine analgesia in both sexes and yet there was an attenuation of tolerance only in males, this suggested that the male-specific attenuation of tolerance was not simply due to a male-specific enhancement (or blockade) of acute morphine analgesia during treatment.
Robust sex differences were observed in the effect of both non-competitive and competitive NMDA receptor antagonists on the development of morphine analgesic tolerance.
In the hot plate assay, MK-801 and the competitive NMDA receptor antagonist CPP attenuated the development of morphine tolerance in male, but not female mice (Figures 1 and 2 ). Because competitive NMDA receptor antagonists were previously reported to produce equal effects on acute morphine analgesia between sexes in mice (51), this further suggested different mechanisms in NMDA receptor modulation of acute morphine analgesia and tolerance between the sexes. Additionally, in contrast to a previous report of an ovariectomy-induced instatement of the male-like enhancement of morphine analgesia by the non-competitive NMDA receptor antagonist dextromethorphan in females (25) , here, ovariectomy had no effect on the lack of attenuation of morphine tolerance by MK-801.
One possibility for the male-specific attenuation of morphine tolerance by MK-801 in the hot plate assay could involve motor impairment due to a number of factors including neurobehavioral toxicity or adaptations that could oppose repeated MK-801-induced behavioral effects such as baseline hypoactivity following repeated hyperactivity (42) or changes in motor coordination following repeated ataxia (12) which could confound the hot plate response.
However, in the first experiment using lower doses of MK-801 and morphine (Figure 1 ), no observable behavioral deficits were observed during acute or chronic treatment, or at the time of testing, as previously reported (26). Additionally, following the regimen of escalating doses, on test day, we observed no visible baseline ataxia or morphine-induced ataxia in any of the groups.
Last, the potential for male-specific impairment of motor coordination following the regimen of escalating doses seems unlikely given that, at least in rats, females are much more sensitive to the acute behavioral effects of MK-801 (30) . A more plausible explanation is that females develop greater tolerance to the neurobiologic effects of MK-801 on the glutamate system that are responsible for disrupting tolerance (e.g., via an upregulation of glutamate transmission or receptors).
Male and female mice (31, 37) and rats (4, 17, 35, 60) can differ in the degree of morphine tolerance. In some cases, the greater sensitivity of males to acute morphine analgesia could account for the greater tolerance observed in male rats (6) or in female rats at a particular phase of the estrus cycle (56) . In the present study, the estrus cycle phase may have contributed to the variability in the magnitude of tolerance across experiments. However, the sex difference with escalating morphine doses and the hot plate), and more tolerance than males in another experiment ( Figure 2 G, H; CPP with escalating doses and the hot plate), yet NMDA receptor antagonism never had an effect on the development of morphine tolerance in females. This is strong evidence that the sex difference in the effect of NMDA receptor antagonists on the development of morphine tolerance is not due to an interaction of tolerance magnitude with chronic NMDA receptor antagonism. It is still possible that either higher or lower doses of MK-801 would affect morphine tolerance in female mice. However, in male mice, a lower dose of MK-801 (0.3 mg/kg, i.p.) had absolutely no effect on the development of morphine tolerance in the hot plate assay following escalating doses of morphine (data reported in Results). We did not attempt to test higher doses in females due to the increased potential for lethality with morphine (63) In the hot plate assay, repeated administration of MK-801 with morphine led to a reliable baseline hypoalgesia in males (Table 1 and 2) and this was also observed in ovx females (Table 2) . However, the hypothesis that baseline hypoalgesia contributes to the male-specific attenuation of morphine tolerance in the hot plate assay was not supported by the observation that neither sex demonstrated baseline hypoalgesia after repeated CPP plus morphine (Table 2 ), yet CPP completely blocked morphine tolerance exclusively in males. Secondly, ovariectomy instated the male-like baseline hypoalgesia (Table 2 ), yet there was no effect on morphine tolerance (Figure 3) . Thus, although males appear more susceptible to baseline hypoalgesia following repeated co-administration of MK-801 with morphine, this observation is not related to the male-specific attenuation of morphine tolerance.
In the tail withdrawal assay, MK-801 administration prolonged acute morphine analgesia similarly in both sexes (Figure 4 A, B ), yet by itself, produced hyperalgesia as previously reported in mice using the tail pinch test (50) and in rats using the hot plate assay (1).
Furthermore, repeated MK-801 reduced the acute analgesic effect of morphine in the tail withdrawal assay but not the hot plate assay at thirty minutes after a morphine challenge without affecting baseline nociception at the time of testing (Figure 4 ). This observation is consistent with cross-tolerance. Although we currently do not have an explanation for cross-tolerance between MK-801 and morphine, it should be noted that repeated MK-801 produces crosssensitization to the locomotor stimulatory effect of morphine (32), highlighting at least one other opioid adaptive behavior that can be established by prior MK-801 exposure. Additionally, experimentally-induced hyperalgesia can produce cross-tolerance to morphine analgesia in the absence of any change in baseline latency at the time of testing (34) . Thus, repeated MK-801-induced hyperalgesia could contribute to the cross-tolerance observed in both sexes in the tail withdrawal assay, perhaps via sensitization of pro-nociceptive processes as observed with opioid-induced hyperalgesia (14).
In the tail withdrawal assay, there was a male-specific enhancement of the development of morphine-induced hyperalgesia by MK-801. This was associated with a male-specific facilitation of morphine tolerance ( Figure 4E ). To our knowledge, there are no other studies that have examined the modulation of morphine tolerance with MK-801 using both the hot plate and tail withdrawal assays and employing the same drug regimen. It is possible that the parameters could be optimized for observing attenuation of morphine tolerance using the tail withdrawal assay. Nevertheless, given the male-specific attenuation of tolerance in the hot plate assay, the male-specific facilitation in the tail withdrawal assay was unexpected and demands some consideration. First, most studies demonstrating an attenuation of morphine tolerance by MK-801 have been conducted in rats and only one report tested C57BL/6J mice. In the publication utilizing the C57BL/6J strain, the hot plate was used to demonstrate an attenuation of morphine tolerance and not the tail flick or tail withdrawal assays (26). Here, using almost the exact same regimen, we replicated the attenuation of tolerance in the hot plate assay with males ( Figure 1) .
A second point is that mouse strains and rat strains differ vastly in their susceptibility to morphine tolerance (28, 36, 46) and it is likely that NMDA receptor antagonism would differentially interact with tolerance across mouse strains which, in turn, may also depend on the pain assay. C57BL/6J mice are particularly susceptible to morphine tolerance as evidenced by the tail withdrawal assay (36) . This could explain why an attenuation of morphine tolerance by MK-801 using the tail withdrawal or tail flick assay has yet to be demonstrated in this strain.
One last consideration is that a difference in stimulus intensity between the two pain assays could explain the different results. Relatedly, changing the stimulus intensity could eliminate the sex difference observed in either assay.
Chronic MK-801 administration alone can produce changes in transcription or expression of NMDA receptor subunits (41), GABA A receptor subunits (38, 47) , several genes involved in synaptic plasticity (52) , striatal dopamine receptors (22, 39, 49) , beta-adrenergic receptors (54), and kappa receptors (10) . Due to the importance of these neurotransmitter systems in baseline nociception, morphine analgesia, tolerance, and dependence, it is likely that repeated administration of MK-801 affects many pathways at several different levels of the CNS involved in these behaviors. Thus, it is probable that rather than chronic NMDA receptor antagonism exclusively preventing morphine-induced neuroplasticity, it induces a separate neuroplasticity that interacts with chronic morphine and present itself differently on a behavioral level between the two pain assays (e.g., because of the difference in circuitry). Support for this hypothesis comes from the increase in baseline latency that occurs in the hot plate, but not the tail withdrawal assay following repeated administration of MK-801 alone. Second, the same treatment produces cross-tolerance in the tail withdrawal assay but not the hot plate assay.
Ovariectomy in adult mice had no effect on the lack of attenuation of morphine tolerance by MK-801 in the hot plate assay (Figure 3 ) which is in contrast to the modulation of acute morphine analgesia by the non-competitive NMDA receptor antagonist dextromethorphan (25) .
However, because we did not monitor the estrtus cycle and because chronic morphine disrupts the estrus cycle (17) , it is still possible that chronic morphine decreases gonadal hormone levels in normal and sham mice that is comparable to ovx mice and this mediates the female phenotype.
It is also possible that chronic MK-801 disrupts the estrus cycle in a similar manner which could account for the lack of effect of ovariectomy. Last, male gonadectomy could result in a female phenotype, as testosterone has been shown to modulate morphine analgesia during chronic treatment (60). A complete study examining the activational and organizational effects of gonadal hormones will be necessary to determine which effects are more important in contributing to the sex difference in the modulation of morphine tolerance by NMDA receptor antagonists.
Given the lack of effect of ovariectomy on the female phenotype for morphine tolerance, it is relevant to consider other findings on sex differences related to MK-801 and morphine that similarly are not affected by ovariectomy. One report indicates that morphine causes greater activation of c-fos, a transcription factor associated with neuronal activation, in the intralaminar thalamic nuclei of male rats. In contrast, MK-801 causes greater activation in the nuclei of female rats, a sex difference not affected by ovariectomy (18) . These nuclei are highly involved in pain processing with many spinothalamic axons terminating in this area (2) . Intralaminar neurons respond to noxious stimuli (19, 55, 66) and terminate in the anterior cingulate cortex and amygdala. Both of these brain areas are involved in the motivational-affective component of pain (23, 33, 61) and contribute to the baseline hot plate response (43, 53, 65) , but not the baseline tail flick response (27, 45, 53) . Thus, sex differences in c-fos activation produced by morphine and MK-801 in the intralaminar nuclei could contribute to the male-specific attenuation of morphine tolerance that was observed exclusively in the hot plate assay (e.g., via differential changes in gene expression).
In sum, NMDA receptor antagonism produces a male-specific attenuation of the development of morphine analgesic tolerance in the hot plate assay and a male-specific facilitation of tolerance in the tail withdrawal assay. This sex difference in the tolerance phenotype is most likely not related to differences in modulation of acute morphine analgesia as both males and females showed a similar prolongation by MK-801. We conclude that male C57BL/6J mice are considerably more sensitive than female mice to perturbations in nociception and analgesia following repeated co-administration of NMDA receptor antagonists with morphine. Mice were treated twice daily for 6 days with MK-801 (0.25 mg/kg, i.p.) followed 30 min later by morphine (10 mg/kg, s.c.). On day 7, baseline hot plate latencies were measured. Data are presented as the mean baseline latency ± S.E.M. "*" = significantly different from control mice receiving chronic saline. An alpha level of 0.05 was considered significant. . On day 7, baseline hot plate or tail withdrawal latencies were measured. "*" = significantly different from control mice receiving chronic saline. "**" = significantly different from mice receiving repeated morphine. An alpha level of 0.05 was considered significant. "Sx" = surgery. "Tx" = treatment. 
